References
- Farkouth ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol. 2009; 103(9): 1227–1237.
- Olsen AS, Fosbøl EL, Lindhardsen J, et al. Long-term cardiovascular risk of NSAID use according to time passed after first-time myocardial infarction: a nationwide cohort study. Circulation. 2012; 126(16): 1524–4539.
- Fosbøl EL, Folke F, Jacobsen FS, et al. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among healthy individuals. Circulation. 2010; 3(4): 395–405.
- European Medicines Agency. PRAC recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors. EMA; 2013.
- McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Medicine. 2011; 8(9): e1001098.
- Aneja A, Farkouh ME. Review: adverse cardiovascular effects of NSAIDs: driven by blood pressure or edema? Therap Adv Cardiovas Disc. 2008; 2(1): 53–66.
- McAdam BF, Lawson FC, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999; 96(1): 272–277.
- Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet. 2007; 370(9605): 2138–2151.
- Brueggmann LI, Mani BK, Mackie AR, et al. Novel actions of nonsteroidal anti-inflammatory drugs on vascular ion channels: accounting for cardiovascular side effects and identifying new therapeutic applications. Mol Cell Pharmacol. 2010; 2(1): 15–19.
- Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008; 372(9651): 1756–1764.
- Chan FKL, Abraham NS, Scheiman JM, Laine L. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the first international working party on gastrointestinal and cardiovascular effects of nonsteroidal anti-inflammatory drugs and anti-platelet agents. Am J Gastroenterol. 2008: 103(11): 2908–2918.